Zobrazeno 1 - 10 of 65 pro vyhledávání: '"Eleni, Gourni"'
1
Akademický článek
Tailoring Fibroblast-Activation Protein Targeting for Theranostics: A Comparative Preclinical Evaluation of the 68Ga- and 177Lu-Labeled Monomeric and Dimeric Fibroblast-Activation Protein Inhibitors DOTA.SA.FAPi and DOTAGA.(SA.FAPi)2
Autor: Tilman Läppchen, Adrianna Bilinska, Eirinaios Pilatis, Elena Menéndez, Surachet Imlimthan, Euy Sung Moon, Ali Afshar-Oromieh, Frank Rösch, Axel Rominger, Eleni Gourni
Publikováno v: Molecules, Vol 29, Iss 13, p 3093 (2024)
Background: FAP radiopharmaceuticals show promise for cancer diagnosis; however, their limited tumor residency hinders treatment. This study compared two FAPi derivatives, DOTA.SA.FAPi and DOTAGA.(SA.FAPi)2, labeled with gallium-68 and lutetium-177,
Externí odkaz: https://doaj.org/article/285d4217cb994469b1b11d23d67b90fa
Zobrazit plný text záznamu
2
Akademický článek
GRPR-targeting radiotheranostics for breast cancer management
Autor: Alice D’Onofrio, Swantje Engelbrecht, Tilman Läppchen, Axel Rominger, Eleni Gourni
Publikováno v: Frontiers in Medicine, Vol 10 (2023)
Breast Cancer (BC) is the most common cancer worldwide and, despite the advancements made toward early diagnosis and novel treatments, there is an urgent need to reduce its mortality. The Gastrin-Releasing Peptide Receptor (GRPR) is a promising targe
Externí odkaz: https://doaj.org/article/d800166837b94aada0fe363fec5401d8
Zobrazit plný text záznamu
3
Akademický článek
Effect of the versatile bifunctional chelator AAZTA5 on the radiometal labelling properties and the in vitro performance of a gastrin releasing peptide receptor antagonist
Autor: Michael Hofstetter, Euy Sung Moon, Fabio D’Angelo, Lucien Geissbühler, Ian Alberts, Ali Afshar-Oromieh, Frank Rösch, Axel Rominger, Eleni Gourni
Publikováno v: EJNMMI Radiopharmacy and Chemistry, Vol 5, Iss 1, Pp 1-19 (2020)
Abstract Background Gastrin Releasing Peptide receptor (GRPr)-based radioligands have shown great promise for diagnostic imaging of GRPr-positive cancers, such as prostate and breast. The present study aims at developing and evaluating a versatile GR
Externí odkaz: https://doaj.org/article/4a0fe7b14d8f475ab34e7db297ebd9f2
Zobrazit plný text záznamu
5
Akademický článek
New Frontiers in Cancer Imaging and Therapy Based on Radiolabeled Fibroblast Activation Protein Inhibitors: A Rational Review and Current Progress
Autor: Surachet Imlimthan, Euy Sung Moon, Hendrik Rathke, Ali Afshar-Oromieh, Frank Rösch, Axel Rominger, Eleni Gourni
Publikováno v: Pharmaceuticals, Vol 14, Iss 10, p 1023 (2021)
Over the past decade, the tumor microenvironment (TME) has become a new paradigm of cancer diagnosis and therapy due to its unique biological features, mainly the interconnection between cancer and stromal cells. Within the TME, cancer-associated fib
Externí odkaz: https://doaj.org/article/c92b212da1a04611a9f34e3bc1ee26ea
Zobrazit plný text záznamu
6
Akademický článek
Radiochemistry and Preclinical PET Imaging of Ga-Desferrioxamine Radiotracers Targeting Prostate-Specific Membrane Antigen
Autor: Eleni Gourni PhD, Luigi Del Pozzo BSc, Mark Bartholomä PhD, Yvonne Kiefer BSc, Philipp T. Meyer MD, PhD, Helmut R. Maecke PhD, Jason P. Holland D.Phil
Publikováno v: Molecular Imaging, Vol 16 (2017)
Radiotracers incorporating the urea-based Glu-NH-C(O)-NH-Lys group have gained prominence due to their role in targeting prostate-specific membrane antigen (PSMA)—a clinical biomarker of prostate cancer. Here, the synthesis, radiolabeling, and in v
Externí odkaz: https://doaj.org/article/80fc5fd6557c4066a3ee4da24b33cef8
Zobrazit plný text záznamu
7
Akademický článek
(R)-NODAGA-PSMA: A Versatile Precursor for Radiometal Labeling and Nuclear Imaging of PSMA-Positive Tumors.
Autor: Eleni Gourni, Coline Canovas, Victor Goncalves, Franck Denat, Philipp T Meyer, Helmut R Maecke
Publikováno v: PLoS ONE, Vol 10, Iss 12, p e0145755 (2015)
PURPOSE:The present study aims at developing and evaluating an urea-based prostate specific membrane antigen (PSMA) inhibitor suitable for labeling with 111In for SPECT and intraoperative applications as well as 68Ga and 64Cu for PET imaging. METHODS
Externí odkaz: https://doaj.org/article/33c99b2cb1fd46f39c28eaa4110a8fb1
Zobrazit plný text záznamu
10
Is Hypoxia a Factor Influencing PSMA-Directed Radioligand Therapy?-An In Silico Study on the Role of Chronic Hypoxia in Prostate Cancer
Autor: Ali Afshar-Oromieh, Volker Morath, Matthias Eiber, Gabriele Birindelli, Milos Drobnjakovic, Wolfgang A. Weber, Calogero D'Alessandria, Kuangyu Shi, Eleni Gourni, Katja Steiger, Axel Rominger
Publikováno v: Birindelli, Gabriele; Drobnjakovic, Milos; Morath, Volker; Steiger, Katja; D'Alessandria, Calogero; Gourni, Eleni; Afshar-Oromieh, Ali; Weber, Wolfgang; Rominger, Axel; Eiber, Matthias; Shi, Kuangyu (2021). Is Hypoxia a Factor Influencing PSMA-Directed Radioligand Therapy?-An In Silico Study on the Role of Chronic Hypoxia in Prostate Cancer. Cancers, 13(14) MDPI AG 10.3390/cancers13143429
Cancers
Volume 13
Issue 14
Cancers, Vol 13, Iss 3429, p 3429 (2021)
Radioligand therapy (RLT) targeting prostate specific-membrane antigen (PSMA) is an emerging treatment for metastatic castration-resistant prostate cancer (mCRPC). It administrates 225Ac- or 177Lu-labeled ligands for the targeted killing of tumor cel
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::91eb01d578b7aa331a8768d2782cfd18
https://boris.unibe.ch/161778/1/cancers-13-03429.pdf
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje